Maleimide-Decorated PEGylated Mucoadhesive Liposomes for Ocular Drug Delivery

Roman V. Moiseev,* Daulet B. Kaldybekov,* Sergey K. Filippov, Aurel Radulescu, and Vitaliy V. Khutoryanskiy*

ABSTRACT: Liposomes are promising spherical vesicles for topical drug delivery to the eye. Several types of vesicles were formulated in this study, including conventional, PEGylated, and maleimide-decorated PEGylated liposomes. The physicochemical characteristics of these liposomes, including their size, zeta potential, ciprofloxacin encapsulation efficiency, loading capacity, and release, were evaluated. The structure of these liposomes was examined using dynamic light scattering, transmission electron microscopy, and small angle neutron scattering. The ex vivo corneal and conjunctival retention of these liposomes were examined using the fluorescence flow-through method. Maleimide-decorated liposomes exhibited the best retention performance on bovine conjunctiva compared to other types of liposomes studied. Poor retention of all liposomal formulations was observed on bovine cornea.

INTRODUCTION

The number of people with visual impairment is around 12 million in the United States and over 2.2 billion worldwide. The human eye is a complex organ with natural barriers for intraocular drug permeation. Recently, two main approaches have been explored to overcome these limitations, such as enhancing drug penetration into ocular tissues and extending the duration of ocular residence. Both approaches could potentially lead to improved drug bioavailability.

Penetration enhancers are a diverse group of chemical substances facilitating drug permeation through the ocular membranes including cyclodextrins (e.g., hydroxypropyl-β- and γ-cyclodextrins), chelating agents (i.e., ethylenediamine-N,N,N′,N′-tetraacetic acid), crown ethers, surfactants (e.g., Tween-20, polyethylene glycol (PEG) esters), bile acids and bile salts, cell-penetrating peptides, and other amphiphilic molecules (i.e., fatty acids, semifluorinated alkanes, etc.).

PEG is a hydrophilic polymer and is widely used in pharmaceutical formulations. PEGylation is an established approach to improve pharmaceutical properties of nanoparticles; e.g., it increases stability of nanoparticles and improves their mucus penetration properties. In ocular drug delivery, PEGylation is used to facilitate paracellular transport of drug molecules by inducing a reversible loosening of the epithelial tight junctions. For example, Eid et al. demonstrated accelerated permeation through the cornea for PEGylated lipid nanoparticles with a moderate increase in mucoadhesive properties. At the same time, according to Abdul Nasir et al., absorption of PEGylated liposomes was slower compared to non-PEGylated nanoparticles, which might be explained by higher resistance to phagocytosis. This might provide a more sustainable drug release. The colloidal stability of PEGylated nanoparticles is thought to be higher with greater molecular weight of PEG due to the more evident steric repulsion. Balguri et al. showed that transcorneal permeation of molecules was optimal for PEG with molecular weight ranging from 2000 to 5000 Da. Nevertheless, some researchers have reported the presence of anti-PEG antibodies in patients' blood, possibly leading to lower drug efficacy and faster blood clearance. PEGylation remains the gold standard in modifying nanocarriers for drug delivery.

There are several strategies to extend the duration of ocular residence time of the drug formulations, including the use of in situ gelling systems divided into three groups according to their phase transition properties: thermosensitive (e.g., Pluronic F127), pH-sensitive (i.e., cellulose acetates and carbomers), and ionic strength sensitive (e.g., gellan gum). In addition, corneal and conjunctival surfaces are covered with the protective negatively charged glyocalyx. Hence, mucoadhesive polymers are also commonly used to extend retention time. Depending on the mechanism of action, these polymers can be classified as those favoring ionic interactions (a); those
forming strong hydrogen bonds with carboxyl, hydroxyl, and amino groups (b); polymers with high molecular weight (e.g., >100 000 Da in general) and chain flexibility, which are able to interpenetrate into the mucus and forming chain entanglements (c); polymers with surface energy facilitating spreading on the mucus (d). The mucoadhesive properties of these polymers are mostly based on the mix of several mentioned mechanisms. Thus, ionic interactions (positively charged amino groups of chitosan interact with the negatively charged sialic and sulfonic acids present in the mucin layer), hydrogen bonding, and chain entanglements are the adhesion mechanisms of chitosan, which is considered a gold standard for mucoadhesive polymers. Chitosan and other cationic and anionic polymers belong to the first generation of mucoadhesive polymers (nonspecific mucoadhesion) and are widely used for enhancing mucoadhesive properties of various formulations. Bernkop-Schnürch has developed so-called thiomers (thiolated polymers) as the second generation of mucoadhesive polymers (specific mucoadhesion). Thiol functional groups present in thiomers form covalent disulfide bonds with cysteine residues of mucins produced. They also could facilitate permeation through loosening of tight junctions due to the interaction with thiol ligands of cysteine-bearing membrane receptors and enzymes.

Maleimide is an unsaturated imide widely used for antibody–drug conjugation. At the same time, it is also known for its mucoadhesive properties due to the formation of carbon–sulfur bonds with thiol groups from the glycocalyx. It was previously demonstrated by our research group that maleimide-bearing nanogels exhibited improved retention on the conjunctival surface. In addition, maleimide-functionalized nanoparticles and liposomes have shown good mucoadhesive properties for intravesical drug delivery. Shitenberg et al. demonstrated the enhanced mucoadhesive properties of alginate modified with maleimide-terminated PEG drug carriers.

Liposomes are spherical vesicles formed of phospholipid bilayers surrounding an aqueous core. These formulations can contain both hydrophilic and hydrophobic drugs. Liposomal formulations have been demonstrated to deliver drugs to the eye by various researchers over the last few decades. In addition, modification of the liposomal surface with mucoadhesive polymers (e.g., hyaluronic acid) is a well-known strategy to prolong their retention time on the ocular surface.

In this study, conventional (CL), PEGylated liposomes (with PEG of different molecular weights of 1000 (LPEG1000), 2000 (LPEG2000), 3000 (LPEG3000), and 5000 Da (LPEG5000)) and liposomes decorated with maleimide-terminated PEG (LPEG2000-Mal) were prepared. The size and morphology of these liposomes were characterized using dynamic light scattering (DLS), transmission electron microscopy (TEM), and small-angle neutron scattering (SANS). Encapsulation efficiency (EE%), loading capacity (LC%), and in vitro cumulative release of hydrophilic ciprofloxacin-HCl were performed for CL, LPEG2000, and LPEG2000-Mal. Additionally, in vitro retention studies on the bovine conjunctival and corneal tissues were conducted for CL, LPEG2000, and LPEG2000-Mal with encapsulated hydrophilic sodium fluorescein (NaFl).

## MATERIALS AND METHODS

**Materials.** Soybean l-α-phosphatidylcholine (PC) was purchased from Alfa Aesar (Heysham, UK). 1,2-Distearoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (ammonium salt) with different molecular weights of 1000, 2000, 3000, and 5000 Da (DSPE-mPEG1000, DSPE-mPEG2000, DSPE-mPEG3000, and DSPE-mPEG5000) and 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-(maleimide(polyethylene glycol)-2000) (ammonium salt) (DSPE-G2000-Mal) were purchased from Avanti Polar Lipids Inc. (Alabaster, USA). Cholesterol (CHO), ciprofloxacin hydrochloride (CF), deuterium oxide (D₂O), fluorescein isothiocyanate dextran (FITC-dextran, Mw 3000–5000 Da), fluorescein sodium salt, and sodium bicarbonate were purchased from Sigma-Aldrich (Gillingham, UK). Sodium chloride, calcium chloride dihydrate, and phosphate-buffered saline (PBS) tablets (which were used to make 100 mL of 1 × PBS solution in deionized water, pH 7.40) were purchased from Fisher Scientific (Loughborough, UK).

**Preparation of Liposomes.** The liposomal formulations containing fixed amounts of l-α-phosphatidylcholine (PC), cholesterol (CHO), and PEGylated lipids at molar ratios of 10:2:0 and 10:2:3 mM (Figure S1 and Table S1 in Supporting Information) were prepared using the thin-film hydration and sonication method. Briefly, a mixture of PC, CHO, and PEGylated lipids dissolved in chloroform–methanol (2:1, v/v) was transferred into test tubes. The organic solvent was evaporated under a stream of nitrogen, and a thin film of lipid was formed inside the test tubes. The test tubes were vacuum-dried overnight to remove any residual solvent. Then, a solution of 5 mL of PBS was added to the dried lipid films to generate hydrated liposome vesicles, and the tubes were left for 1 h at room temperature. The tubes were vortex-mixed vigorously for 30 min. These dispersions were then sonicated in a sonication bath (FS200b, Decon Laboratories Ltd., UK) for 30 min to reduce the size of the liposomes. Excess lipids were separated from the vesicle formulations by centrifugation of Eppendorf tubes at 13,000 rpm (7588 × g) for 30 min. The supernatants were collected, filtered using 0.22 μm Minisart syringe filters, and stored in a refrigerator prior to characterization. Liposomal formulations encapsulated with 1 mg/mL NaFl (dissolved in PBS) and 1 mg/mL CF (dissolved in 0.9% NaCl) were prepared as above. Solutions of NaFl or CF were used for hydration of the dried lipid films to form liposomes loaded with NaFl or CF.

**Particle Size and Zeta Potential Measurements.** The size of liposomes, their polydispersity index (PDI), and zeta potential values were determined using dynamic light scattering (DLS) with a Zetasizer Nano-ZS (Malvern Instruments, UK). Each formulation was diluted 100-fold with Milli-Q ultrapure water. A typical liposome refractive index of 1.45 and absorbance of 0.1 were used in all measurements. Each sample was measured three times at 25 °C, and the mean ± standard deviation values were calculated. The normal resolution analysis model (general purpose algorithm) was selected to obtain intensity-weighted distribution functions over relaxation time. As the next step, the distribution functions over the relaxation time were converted to the distribution functions over hydrodynamic diameters using Stokes–Einstein equation. The ζ-potential values were calculated from the measured values of electrophoretic mobilities using DTS-1070 folded capillary tube cuvettes (Malvern, UK). Polydispersity index (PDI) value was calculated as the ratio of second and first cumulants k₂/PDI = k₃/k₁² where cumulants k₁ and k₂ are coefficients in the first and second coefficients in the Taylor series of a correlation function g(r). To obtain the ζ-potential, data was processed using a software analysis model. At least 3 samples were measured and processed using the Smoluchowski model (Fₛ = 1.50) to convert electrophoretic mobility data to ζ-potential.

**Small-Angle Neutron Scattering (SANS) Measurements.** Liposome suspensions were prepared as described above using PBS dissolved in deuterium oxide (D₂O), filtered, and stored in a refrigerator prior to SANS studies. The concentration of nanoparticles used in SANS measurements was ~5 mg/mL for all liposomes.
SANS experiments were performed at MLZ (Garching, Germany) on a KWS-2 instrument.25 Measurements were made on a 3He tube array detector (144 tubes, pixel size 8 mm) using a non-polarized, monochromatic (wavelength $\lambda$ set by a velocity selector) incident neutron beam collimated with rectangular apertures for three sample-to-detector distances, namely, 2, 8, and 20 m ($\lambda = 0.6$ nm). With this setup, the investigated $q$-range was 0.015 nm$^{-1}$ to 4.6 nm$^{-1}$. In all cases, the two-dimensional scattering patterns were isotropic and were azimuthally averaged, resulting in the dependence of the scattered intensity $I(q)$ on the momentum transfer $q = 4\pi \sin \theta / \lambda$, where $\theta$ is the scattering angle. The curves were corrected for the background scattering from the empty cell and for detector efficiency. Hellima Analytics Suprasil 300 high precision quartz cells of 1 and 2 mm thickness were used in these experiments. SANS experiments were performed in D₂O solutions. The D₂O solutions were measured and properly subtracted.

**SANS Data Fitting.** The SANS data were fitted by the combination of two models: the model of a lipid bilayer with Gaussian profile of inner and outer layers and the disk form-factor. The models were implemented in SASFit software. The lipid bilayer is regarded as a planar structure with neutron scattering length for inner hydrophobic and two outer hydrophilic layers (Figure S2). The disc form-factor is taken to describe the local aspect of liposomes, namely, the thickness. Such an assumption is valid since the membrane thickness is much smaller in comparison with the diameter of liposomes. Thus, liposomes can be regarded as flat structures. The final form-factor is taken in the following way:

$$P_{\text{lip}} = [(F_{\text{core}} + 2F_{\text{out}})F_{\text{disc}}]^2$$

Here, $F_{\text{core}} = \frac{1}{2}\pi \sigma_{\text{core}}\sin(q\sigma_{\text{core}})/2$ and $F_{\text{out}} = \frac{1}{2}\pi \sigma_{\text{out}}\sin(q\sigma_{\text{out}})/2$. The fitting parameters for these models are:

- $\sigma_{\text{core}}$: the width of the central Gaussian profile
- $\sigma_{\text{out}}$: scattering length density contrast of the central Gaussian profile
- $\sigma_{\text{in}}$: width of the two outer Gaussian profiles
- $\sigma_{\text{out}}$: scattering length density contrast of the two outer Gaussian profiles
- $z$: the half of the distance between the centers of the outer Gaussian profiles ($z = t/2$)
- $D$: diameter of a planar object ($D = 2R$)
- $SZ$: Schultz-Zimm distribution over radius.

The fitting procedure was started from the fitting of CL where some fitting parameters can be fixed to the values reported in the literature. The values of the fitting parameters obtained for conventional liposomes were taken as initial values for the fitting of the SANS curves of the rest formulations with LPEG1000, LPEG2000, LPEG2000-Mal, LPEG3000, and LPEG5000. The value of $x^2$ was taken as a measure of fitting quality. All values for the diameter obtained from the SANS fitting are below 200 nm, and in the experimental $q$ range the lowest $q = 0.015$ nm$^{-1}$ corresponds to the particle size of 418 nm.

**Transmission Electron Microscopy (TEM).** TEM imaging of liposomes was performed using a JEOl 2100 Plus TEM (JEOL, Ltd., Japan) operated at an acceleration voltage of 200 kV. Specimen preparation included pipetting a drop of purified liposomal suspension (~0.5 mg/mL) onto a parafilm. Then, the drop was covered with the “carbon” side of a glow-discharged holey carbon film-coated 400-mesh copper grid, which was left in contact with each sample for 60 s. A filter paper blotting was used to remove the excess solution. Next, a drop of 1% (w/v) uranyl acetate (UA) solution was placed onto the parafilm, and the “carbon” side with UA was in contact with the grid for 30 s for CL, LPEG2000, and 5 s for the LPEG2000-Mal. Each sample was then picked off as described above, and the sample was allowed to dry at room temperature before being characterized with TEM. Previous studies have reported good image quality from this sample preparation method for PLGA–PEG nanoparticles.

**Encapsulation Efficiency (EE%) and Loading Capacity (LC %).** Encapsulation efficiency (EE%) and loading capacity (LC%) for CL, LPEG2000, and LPEG2000-Mal with encapsulated ciprofloxacin hydrochloride (CF) were quantified using Cary 100 UV–vis spectrophotometer (Agilent Technologies, USA) at an absorbance wavelength of 272 nm (Figure S3) and following a modified protocol reported previously within our research group. Three separate 1 mg/mL solutions of CF were prepared in 0.9% sodium chloride solution. The PBS solution was replaced with 0.9% NaCl, improving the CF’s solubility (pH = 4.84). Then, a calibration curve for CF in 0.9% NaCl solution was produced (Figure 4). Unused Eppendorf tubes were preweighed ($m_{\text{clean Epp}}$) prior to liposome preparation. After centrifugation, during liposome preparation these Eppendorf tubes with separated excess lipids and residual CF were freeze-dried for at least 12 h. Once completely dried, these tubes were weighed ($m_{\text{lipids+CF+Epp}}$). Hence, the weight of the sum of excess lipids and residual CF ($m_{\text{lipids+CF+Epp}}$) was determined using the following equation:

$$m_{\text{lipids+CF+Epp}} = m_{\text{lipids+CF+Epp}} - m_{\text{clean Epp}}$$

Then, the content of each Eppendorf tube was dissolved in MeOH:HCl solution (methanol: hydrochloric acid (1 M) at 70:30 v/v) and transferred into a vial. After 12 h, these solutions (lipids + CF) were 40-fold diluted with 0.9% NaCl solution and analyzed using Cary 100 UV–vis Spectrophotometer. Thus, the concentration of the residual CF ($C_{\text{CF}}$ in Epp) from the $m_{\text{lipids+CF+Epp}}$ was identified. Next, the weight of excess lipids ($m_{\text{lipids in Epp}}$) was calculated using the following equation:

$$m_{\text{lipids in Epp}} = m_{\text{lipids+CF+Epp}} - m_{\text{CF in Epp}}$$

Then, 0.5 mL of the lipid nanocarrier dispersion was placed in an ultratitration flask with the Amicon Ultra-0.5 Ultracel-3 centrifugal filter unit with a molecular weight cutoff of 3000 Da and centrifuged at 13,000 rpm (7558 x g) for 60 min. The filtrate was discarded. Then, 0.25 mL of 0.9% NaCl was added to wash the retentate before further centrifugation for 40 min. This step was repeated twice. The passed solution was also discarded. The liposomes with CF in the retentate were then disrupted with 0.2 mL of MeOH:HCl solution and centrifuged for 10 min. The solution passed through the filter was collected (from the external tube) and transferred to another marked Eppendorf tube (encapsulated CF). This step was repeated by adding 0.2 mL of MeOH:HCl solution and centrifuged at 4 °C for another 10 min. Then both solutions were collected (from the internal and external tubes) and were transferred into the previous Eppendorf tube (encapsulated CF). Then, this sample was 400-fold diluted with 0.9% NaCl solution and analyzed using the UV–vis spectrophotometer. Hence, the weight of the encapsulated CF ($m_{\text{encaps. CF}}$) was identified. The encapsulation efficiency (EE%) and loading capacity (LC%) were calculated using the following equations: where $m_{\text{encaps. CF}}$ is the amount of CF encapsulated in liposomes, $m_{\text{initial CF}}$ is the initial amount of CF (5 mg for 5 mL), $m_{\text{CF in Epp}}$ is the residual amount of CF left in Eppendorf tubes during the liposome preparation; $m_{\text{liposomes}}$ is the total weight of liposomes recovered after centrifugation and $m_{\text{lipids in Epp}}$ is the weight of excess lipids left in Eppendorf tubes after the liposome preparation. All the experiments were conducted five times for each sample.

$$EE\% = \frac{m_{\text{encaps. CF}}}{m_{\text{initial CF}}} \times 100\%$$

$$LC\% = \frac{m_{\text{encaps. CF}}}{m_{\text{liposomes}} - m_{\text{lipids in Epp}}} \times 100\%$$
Table 1. Physicochemical Characteristics of Conventional, PEGylated, and PEG-Mal Liposomes Determined by DLS and SANS

| Liposomal formulations | Mean diameter (nm) | PDI | Zeta potential (mV) | D (nm) | $\sigma_{\text{out}}$ (nm) | $\sigma_{\text{core}}$ (nm) | $\sigma_{\text{core}}$ $10^{-2}$ (Å$^2$) | $\sigma_{\text{core}}$ $10^{-2}$ (Å$^2$) | z (nm) |
|------------------------|-------------------|-----|-------------------|--------|----------------|----------------|----------------|----------------|--------|
| CL                     | 101 ± 1           | 0.156 | −58 ± 1           | 139    | 0.54          | 13.2           | 0.3            | 1.8            |
| LPEG1000               | 110 ± 1           | 0.221 | −53 ± 1           | 158    | 1.05          | 9.9            | 0.2            | 1.4            |
| LPEG2000               | 94 ± 1            | 0.207 | −41 ± 1           | 110    | 0.59          | 7.7            | 0.8            | 1.7            |
| LPEG2000-Mal           | 97 ± 1            | 0.228 | −42 ± 1           | 124    | 0.54          | 6.6            | 0.6            | 1.7            |
| LPEG3000               | 93 ± 1            | 0.227 | −36 ± 1           | 102    | 0.45          | 9.1            | 3.1            | 1.8            |
| LPEG5000               | 83 ± 1            | 0.210 | −29 ± 1           | 86     | 0.41          | 11.1           | 3.7            | 1.5            |

Cumulative Drug Release. *In vitro* cumulative release of CF from CL, LPEG2000, and LPEG2000-Mal was quantified using the UV–vis spectrophotometer at 272 nm. First, 2 mL of each liposomal formulation containing CF was transferred into Pur-A-Lyzer Maxi 3500 dialysis tubing (molecular weight cutoff 3500 Da) and immersed in 30 mL of 0.9% NaCl (pH = 7.40), used as a medium, within 50 mL Falcon tubes. Then, these Falcon tubes were shaken in a water bath at 80 rpm for 24 h at 37°C. At predetermined time intervals (10, 20, and 30 min, and 1, 2, 4, 8, 12, 18, and 24 h), the aliquots (5 mL) were withdrawn from the dialysate and replaced with fresh medium maintaining a constant volume of 30 mL. These aliquots were analyzed without dilution using the UV–vis spectrophotometer (Table S3 in Supporting Information). The cumulative release % for each time point was calculated using the following equation:

\[
\text{Cumulative release } \% = \frac{m_{\text{out,caps, CF}} + m_{\text{out,b} + b} + m_{\text{out,caps, CF}}}{100}
\]

where $m_{\text{out,caps, CF}}$ is the amount of CF encapsulated in liposomes, $m_{\text{out,b}}$ is the amount of CF in mL measured in the first time point (10 min), $m_{\text{out,b}}$ is the amount of CF in mL measured in the next time point, $m_{\text{out,b}}$ is the amount of CF in 30 mL measured at the time point of $b$ (for instance, 20 min). All the experiments were conducted five times for each sample. Then, these cumulative release data were analyzed and fitted using the first-order kinetic model with OriginPro 9.8.0.200 software.

In Vitro Retention Studies on Ocular Tissues. The retention properties of CL, LPEG2000, and LPEG2000-Mal with encapsulated 1 mg/mL of NaFl compared to the negative control (1 mg/mL of STF) were slightly greater than LPEG2000 with the significant difference ($p < 0.05$). However, no differences were observed between LPEG1000 and LPEG2000-Mal. These data are presented in Table 1 and Figure 1. One-way ANOVA testing demonstrated that there were statistically significant differences between CL and PEGylated liposomes, including LPEG2000-Mal, but no difference was observed between LPEG2000 and LPEG3000 ($p > 0.05$). This is also interesting to note that LPEG1000 are significantly greater in size than CL. This could be related to the presence of PEG corona. LPEG2000-Mal were slightly greater than LPEG2000 with the significant

![Figure 1](https://doi.org/10.1021/acs.langmuir.2c02086)
difference ($p < 0.05$) between LPEG2000 and LPEG2000-Mal. This can be explained by the presence of the terminal maleimide groups. On the other hand, LPEG5000 displayed a particle size even smaller than CL. This could be related to a slightly different structural organization of their core. According to the literature, the most optimal size of nanoparticles for uptake by the conjunctiva and cornea is considered to be less than 200 nm. Moreover, the obtained size
data demonstrate the presence of small unilamellar vesicles, which are widely used in clinically approved products.\textsuperscript{27} The polydispersity index (PDI) of all types of liposomes was \( < 0.23 \), indicating a homogeneous liposomal population with a narrow size distribution. The PDI is a measure of the size distribution, and according to the literature, liposome formulation is considered to be heterogeneous if PDI is \( \geq 0.30 \).\textsuperscript{40} Vesicles showing their zeta potential less than \( -30 \text{ mV} \) are believed to have good colloidal stability of the nanodispersion system and have a reduced number of bilayer membranes due to the electrostatic repulsion between charges of the same polarity.\textsuperscript{41} Additionally, liposomal formulation with \( \leq -30 \text{ mV} \) would have higher entrapment capacity, because stronger zeta potential contributes to the increase in the unilamellar vesicles.\textsuperscript{42}

The negative staining TEM analysis with uranyl acetate was used to confirm the size and morphology of CL, LPEG2000, and LPEG2000-Mal, and the microphotographs are shown in Figure 2. The obtained data demonstrated that homogeneous liposomes were formed with clear spherical morphology, confirming the DLS data (Table 1).

**SANS.** Having obtained the proof of a vesicular structure from TEM experiments, SANS experiments were performed to shed light on the detailed information in the liposome membrane. All SANS curves were successfully fitted by the model described above (Table 1, Figure 3 (A and B)) giving additional confirmation of the vesicular morphology of the nanoparticles. Several features should be noted here. Visual inspection of the scattering curves gives evidence of the lack of the drastic changes in liposome structure with increasing PEG length; liposomes preserve their bilayered structure with incorporation of PEG. Any significant modification of nanoparticle shape such as liposome destruction, vesicle-to-micelle transformation, or strong liposome aggregation would be immediately manifested on a scattering curve.\textsuperscript{43} Second, there is a strong agreement and correlation between the sizes measured by DLS and diameter values obtained from SANS fitting (Table 1). Such an agreement is an additional proof of the good fitting quality. The same as for DLS results, the correlation between the liposomes diameter values and PEG length is visible from the fitting data (Table 1). The Pearson coefficient is \( -0.86 \). The values of interlayer distance \( z \) are barely sensitive to the presence of PEG. The obtained \( z \) values are in agreement with previously reported data.\textsuperscript{24} The SANS data also provide evidence that the width of the outer hydrophilic layer is nearly constant over the PEG length. However, the decrease of the width of the central Gaussian layer from 13.2 to 3.1 nm with the increasing PEG chain implies that the inner hydrophilic layer is getting a more uniform structure. Comparison between the LPEG2000 and LPEG2000-Mal samples with and without maleimide groups shows that maleimide groups are possibly partially incorporated into a hydrophobic shell making it less uniform than the Mal-free sample.

**Encapsulation Efficiency (EE%) and Loading Capacity (LC%).** The pH of CF solution was measured as 4.84 \( \pm \) 0.01. Ideally, it is recommended to formulate eye drops with a pH close to the physiological pH of tear fluid in order to reduce discomfort and minimize lacrimation. Still, a human eye can tolerate topical ophthalmic formulations with pH values between 3.5 and 9.\textsuperscript{27} In addition, the pH of the commercially available CF eye drops is \(~4.5\).\textsuperscript{45} The entrapment efficiency and loading capacity values of CL, LPEG2000, and LPEG2000-Mal are within the ranges of 27\%–28\% and 1–5\%, respectively, without any statistically significant difference between them (Table S2 in Supporting Information). These figures are broadly comparable to the literature sources.\textsuperscript{45} Hosny reported figures of EE% for their liposomes within the liposomal hydrogel as high as 82\%, which might be explained with a different liposomal composition including the addition of stearylamine and dicetyl phosphate.\textsuperscript{46}
reaching up to 40% of the average figure might be explained by the presence of multilamellar liposomes in the population.

**In Vitro Cumulative Release.** A dialysis method was used to determine the cumulative release profile of CF from CL, LPEG2000, and LPEG2000-Mal at 37 °C in STF solution. The experimental cumulative release profiles are presented in Figure 4, while numerical values are shown in Table S3 in Supporting Information. All cumulative release curves were successfully fitted using the first-order kinetics model (Figure S4 in the Supporting Information), considered to be a common drug release model for liposomal formulations. Interestingly, the drug release profiles from the CL, LPEG2000, and LPEG2000-Mal were similar, reaching ∼100% by ∼12–18 h without statistically significant difference between them. According to the literature data, the unilamellar liposomes with a hydrodynamic diameter of ∼130 nm exhibit a higher drug release rate compared to the multilamellar liposomes with two or three bilayers and a diameter of ∼250 nm. In general, this difference in release rate results from the number of phospholipid bilayers the encapsulated drug needs to cross.47

**In Vitro Retention Studies on Ocular Tissues.** The corneal epithelium is known to be the major barrier to topical drug delivery to the eye.48 On the other hand, stromal permeability is dependent on the molecule radius, providing a strong limitation for lipophilic compounds of small size (radius

---

Figure 7. Structure of liposomes functionalized with maleimide groups (LPEG2000-Mal) and their possible reaction with thiol groups present on the cornea and conjunctiva.
<10 Å). Interestingly, the endothelium layer is slightly less permeable to small lipophilic molecules than the corneal stroma. Macromolecules, however, cross the endothelium more readily than stroma. According to the literature, the conjunctiva is 8.6 ± 4.4-fold more permeable than the cornea.\(^{49}\) Hamalainen et al.\(^{50}\) demonstrated greater permeability of a rabbit’s conjunctiva compared to the corneal tissues for the mixture of PEGs with the mean molecular weights of 200, 400, 600, and 1000 Da.

The results generated during the in vitro retention experiments supported these data. Thus, CL, LPEG2000, and LPEG2000-Mal with 1 mg/mL NaFl demonstrated very poor retention on ex vivo bovine cornea (Figure 5A and Figure 6 (A and C)), and average fluorescence values can be found in Table S4 in Supporting Information. All three types of liposomes were washed off the corneal surface by the fifth minute. At the same time, no statistically significant difference was detected between these liposomes for area under the curve (AUC) calculations for the total time of the mucoadhesion experiment (0 to 30 min with 5 min increments).

A completely different retention of liposomes is observed for the bovine conjunctival tissues. These results with the exemplar images are presented in Figure 5B and Figure 6B,D. The average fluorescence values and AUC figures are shown in Table S5 in Supporting Information. After the first 5 min of STF washing, significantly greater retention of LPEG2000-Mal was observed in comparison with the negative control (1 mg/mL FITC-dextran solution) and CL (p < 0.001 and p < 0.01, respectively). There was also a small but significant difference between LPEG2000-Mal and LPEG2000 (p < 0.05). CL demonstrated no statistically significant difference with the negative control. Following 10 min of the experiment LPEG2000-Mal were the only formulations that showed a difference compared to FITC-dextran (p < 0.01). Surprisingly, there was no difference between LPEG2000 and the negative control, which might be potentially explained by the presence of PEG rather than the combination of PEG and maleimide like in LPEG2000-Mal. The same retention was observed after 15 min. From 20 min onward up to 30 min of the retention test, the difference between LPEG2000-Mal and negative control became even higher, reaching p < 0.001. The potential permeation of NaFl through the conjunctiva might explain this higher difference, which results from the prolonged presence of these liposomes on the mucosal surface due to the formation of covalent bonds with thiol groups present in mucins. As a result of these studies, liposomes decorated with PEG with terminal maleimide groups are shown to have the potential for improved retention on the conjunctiva in topical drug delivery to the eye.

### CONCLUSIONS

Conventional, PEGylated (with different molecular weights of 1000, 2000, 3000, and 5000 Da), and maleimide-decorated liposomes were formulated in this study. The physicochemical characteristics of these nanoparticles, encapsulation efficiency, loading capacity, ciprofloxacin drug release, and ex vivo corneal and conjunctival retention were examined. Very poor retention of all liposomal formulations was observed on the cornea, but substantially better retention of these vesicles was seen on the conjunctiva. The maleimide-decorated liposomes demonstrated the best performance on bovine conjunctiva due to the ability of maleimide groups to form covalent bonds with thiol groups present in mucins. As a result of these studies, liposomes decorated with PEG with terminal maleimide groups are shown to have the potential for improved retention on the conjunctiva in topical drug delivery to the eye.

### ASSOCIATED CONTENT

 Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.langmuir.2c02086.

Schematic representation of preparation of CL, PEGylated and PEG-Mal liposomes; SLD profile for a lipid bilayer with a Gaussian electron density distribution; composition (%w/v) of lipid nanocarrier formulations; UV–vis spectra with maximum absorbance peak for CF dissolved in 0.9% NaCl solution; encapsulation efficiency (EE%) and loading capacity (LC%); CF cumulative release (%) from CL, LPEG2000, and LPEG2000-Mal; selected release profiles of CF from CL, LPEG2000, and LPEG2000-Mal; Average fluorescence intensity (a.u.) and AUC values for mucoadhesion tests (PDF)

### AUTHOR INFORMATION

Corresponding Author

Vitaly V. Khutoryanskiy — Reading School of Pharmacy, University of Reading, Whiteknights RG6 6DX Reading, United Kingdom; orcid.org/0000-0002-7221-2630; Phone: +44(0) 118 378 6119; Email: v.khutoryanskiy@reading.ac.uk; Fax: +44(0) 118 378 4703

Authors

Roman V. Moiseev — Reading School of Pharmacy, University of Reading, Whiteknights RG6 6DX Reading, United Kingdom; orcid.org/0000-0002-4358-9981

Daulet B. Kaldybekov — Reading School of Pharmacy, University of Reading, Whiteknights RG6 6DX Reading, United Kingdom; Department of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, 050040 Almaty, Kazakhstan; orcid.org/0000-0002-7191-5465

Sergey K. Filippov — Reading School of Pharmacy, University of Reading, Whiteknights RG6 6DX Reading, United Kingdom

Aurel Radulescu — Forschungszentrum Jülich GmbH, Jülich Centre for Neutron Science (JNCS) at Heinz Maier-Leibnitz Zentrum (MLZ), 85748 Garching, Germany

Complete contact information is available at: https://pubs.acs.org/doi/10.1021/acs.langmuir.2c02086
Author Contributions

*Roman V. Moiseev and Daulet B. Kaldybekov contributed equally. Roman V. Moiseev: Investigation, Data curation, Formal analysis, Writing—original draft, Methodology, Visualization. Daulet B. Kaldybekov: Investigation, Formal analysis, Methodology, Writing—original draft, review and editing. Sergey K. Filippov: Investigation, Writing—original draft. Formal analysis. Aurel Radulescu: Investigation, Formal analysis. Vitaliy V. Khutoryanskiy: Conceptualization, Supervision, Funding acquisition, Methodology, Writing—review and editing.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Miss Amanpreet Kaur (Electron Microscopy Laboratory at Chemical Analysis Facility, University of Reading) for help with TEM experiments. R.V.M. acknowledges the University of Reading for international scholarship funding of his postgraduate studies. V.V.K. acknowledges the financial support provided by the European Union’s Horizon 2020-MSCA-RISE-2018/823883: Soft Biocompatible Polymeric NANOstructures: A Toolbox for Novel Generation of Nano Pharmaceuticals in Ophthalmic (NanoPol). S.K.F. and V.V.K. also acknowledge the Leverhulme Trust for the visiting professorship grant (VP2-2020-013) to support the visit and work of S.K.F. at the University of Reading.

REFERENCES

(1) CDC. Vision Health Initiative (VHI); 2020. https://www.cdc.gov/visionhealth/basics/ced/fastfacts.htm (accessed 10.03.2022).

(2) Kaur, I. P. Ocular Penetration Enhancers. In Enhancement in Drug Delivery, Toutou, E., Ed.; CRC Press, 2006; pp S27–S48.

(3) Moiseev, R. V.; Morrison, P. W.; Steele, P.; Khutoryanskiy, V. V. Penetration enhancers in ocular drug delivery. Pharmaceutics 2019, 11 (7), 321.

(4) Porfyrieva, N.; Moustafine, R.; Khutoryanskiy, V. PEGylated systems in pharmaceutics. Polymer Science, Series C 2020, 62 (1), 62–74.

(5) Mosquera, V. C. F.; Legrand, P.; Morgat, J.-L.; Vert, M.; Mysiakine, E.; Gref, R.; Deissquagut, J.-P.; Barratt, G. Biodistribution of long-circulating PEG-grafted nanoparticles in mice: effects of PEG chain length and density. Pharm. Res. 2001, 18 (10), 1411–1419. Huckleby, J. T.; Lai, S. K. PEGylation for enhancing nanoparticle diffusion in mucus. Advanced drug delivery reviews 2018, 124, 125–139.

(6) Di Prima, G.; Bongiovì, F.; Palumbo, F. S.; Pitarresi, G.; Liccari, M.; Iamonn, G. Mucoadhesive PE-Glyated inulin-based self-assembling nanoparticles: In vitro and in vivo transcorneal permeation enhancement of corticosteroids. Journal of Drug Delivery Science and Technology 2019, 49, 195–208.

(7) Eid, H. M.; Elkomy, M. H.; El Menshawe, S. F.; Salem, H. F. Development, optimization, and in vitro/in vivo characterization of enhanced lip nanoparticles for ocular delivery of ofloxacin: the influence of pegylation and chitosan coating. AAPS PharmSciTech 2019, 20 (S), 1–14.

(8) Abdul Nasir, N. A.; Alyautdin, R. N.; Agarwal, R.; Nukolova, N.; Chekninov, V.; Mohd Ismail, N. Ocular tissue distribution of topically applied PEGylated and non-PEGylated liposomes. Advanced Materials Research 2013, 832, 1–8.
(26) Shitenberg, Y.; Goldfeder, M.; Schroeder, A.; Bianco-Peled, H. Alginate modified with maleimide-terminated PEG as drug carriers with enhanced mucoadhesion. Carbohydr. Polym. 2017, 175, 337-346.

(27) Taylor, K. M.; Aulton, M. E. Aulton’s Pharmaceutics E-Book: The Design and Manufacture of Medicines; Elsevier Health Sciences, 2021.

(28) Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S. W.; Zarzami, N.; Hanifehpour, Y.; Samiei, M.; Kourohi, M.; Nejati-Koshki, K. Liposomes: classification, preparation, and applications. Nanoscale Res. Lett. 2013, 8 (1), 1-9.

(29) Schaefer, H. E.; Krohn, D. L. Liposomes in topical drug delivery. Investigative ophthalmology & visual science 1982, 22 (2), 220-227. Mishra, G. P.; Bagui, M.; Tamboli, V.; Mitra, A. K. Recent applications of liposomes in ophthalmic drug delivery. Journal of drug delivery 2011, 2011, 1. Agarwal, R.; Iezhitsa, I.; Agarwal, P.; Abdul Nasir, N. A.; Razali, N.; Alyautdin, R.; Ismail, N. M. Liposomes in topical ophthalmic drug delivery: an update. Drug delivery 2016, 23 (4), 1075-1091. Bhattacharjee, A.; Das, P. P.; Adhikari, P.; Marbanian, D.; Pal, P.; Ray, S.; Mazumder, B. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery. European journal of ophthalmology 2019, 29 (1), 113-126. Gorantla, S.; Rapalli, V. K.; Waghule, T.; Singh, P. P.; Dubey, S. K.; Saha, R. N.; Singhvi, G. Nanocarriers for ocular drug delivery: Current status and translational opportunity. Rsc Advances 2020, 10 (46), 27835-27855.

(30) Ludwig, A. The use of mucoadhesive polymers in ocular drug delivery. Advanced drug delivery reviews 2005, 57 (11), 1595-1639. Lin, J.; Wu, H.; Wang, Y.; Lin, J.; Chen, Q.; Zhu, X. Preparation and stabilization of multilamellar liposomes at full hydration: full q-angle scattering data analysis using a library of analytical expressions. Langmuir 2000, 16, 7865-7873.

(31) Zaborova, O. V.; Filipov, S. K.; Chytł, P.; Kováčik, L.; Ulbrich, K.; Yaroslavov, A. A.; Etrich, T. A novel approach to increase the stability of liposomal containers via in pre coating by poly [N-(2-hydroxypropyl)methacrylamide] with covalently attached cholesterol groups. Macromol. Chem. Phys. 2018, 219 (7), 1700508. Rangsimamongkong, W.; Opanasopit, P.; Rejanarata, T.; Duangkit, S.; Ngawhirunpat, T. Skin transport of hydrophobic compound-loaded PEGylated lipid nanocarriers: comparative study of liposomes, niosomes, and solid lipid nanoparticles. Biol. Pharm. Bull. 2016, 39 (8), 1254-1262.

(32) Radulescu, A.; Szekely, N. K.; Appavou, M.-S. KWS-2: Small angle scattering diffractometer. Journal of large-scale research facilities JLSRF 2015, I, 29.

(33) Brelleier, I.; Kohlbrecher, J.; Thüenemann, A. F. SASfit: a tool for small-angle scattering data analysis using a library of analytical expressions. Journal of applied crystallography 2015, 48 (5), 1587-1598.

(34) Pabst, G.; Rappolt, M.; Amenitsch, H.; Laggner, P. Structural information from multimellar liposomes at full hydration: full q-range fitting with high quality x-ray data. Phys. Rev. E 2000, 62 (3), 4000.

(35) Cave, R. A.; Cook, J. P.; Connov, C. J.; Khutoryanskiy, V. V. A flow system for the on-line quantitative measurement of the retention of dosage forms on biological surfaces using spectroscopy and image analysis. International journal of pharmaceutics 2012, 428 (1-2), 96-102.

(36) Srividiya, B.; Cardoza, R. M.; Amin, P. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. Journal of controlled release 2001, 73 (2-3), 205-211.

(37) Van Haeringen, N. J. Clinical biochemistry of tears. Survey of ophthalmology 1981, 26 (2), 84-96.

(38) Chang, A. Y.; Purt, B. Biochemistry, Tear Film. In StatPearls [Internet]; National Library of Medicine, 2021.

(39) Mobaraki, M.; Soltani, M.; Zare Harofee, S.; L Zoudani, E.; Daliri, R.; Aghamirsalam, M.; Raahemifar, K. Biodegradable nanoparticle for cornea drug delivery: Focus review. Pharmaceutics 2020, 12 (12), 1232.

(40) Danaei, M.; Dehghankhold, M.; Atei, S.; Hasanazadeh Davaran, F.; Javanmard, R.; Dokhani, A.; Khorasani, S.; Mozafari, M. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018, 10 (2), 57.

(41) Freitas, C.; Müller, R. H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions. International journal of pharmaceutics 1998, 168 (2), 221-229.

(42) Kandzija, N.; Khutoryanskiy, V. Y. Delivery of Riboflavin’S-Monophosphate into the cornea: can liposomes provide any enhancement effects? J. Pharm. Sci. 2017, 106 (10), 3041-3049.

(43) Filippov, S. K.; Hruby, M.; Stepak, P. Small-Angle X-ray and Neutron Scattering of Temperature-Responsive Polymers in Solutions. Temperature-Response Polymers: Chemistry, Properties and Applications 2018, 175-196. Ratsesva, A.; Kaberov, L. I.; Noirez, L.; Ryukhin, V.; Nardin, C.; Verbraeken, B.; Hoogenboom, R.; Stepak, P.; Filippov, S. K. Structural characterization of nanoparticles formed by fluorinated poly (2-oxazoline)-based polyphiles. Eur. Polym. J. 2018, 99, 518-527.

(44) NIH. CIPROFLOXACIN- ciprofloxacin hydrochloride solution/ drops; 2022. https://dailymed.nlm.nih.gov/dailymed/fdaDrugXsd. cfm?setid=3e9a6174-962b-400e-8ca7-4a6c3260a5d&type=display (accessed 15.03.2022).

(45) Al-Joufi, F. A.; Salem-Bekhit, M. M.; Taha, E. I.; Ibrahim, M. A.; Muharram, M. M.; Alshehri, S.; Ghoneim, M. M.; Shakeel, F. Enhancing Ocular Bioavailability of Ciprofloxacin Using Colloidal Lipid-Based Carrier for the Management of Post-Surgical Infection. Molecules 2022, 27 (3), 733. Taha, E. I.; El-Anazi, M. H.; El-Bagory, I. M.; Bayomi, M. A. Design of liposomal colloidal systems for ocular delivery of ciprofloxacin. Saudi Pharmaceutical Journal 2014, 22 (3), 231-239. Budai, L.; Hajdú, M.; Budai, M.; Gróf, P.; Béni, S.; Noszáll, B.; Klebovich, I.; Antal, I. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. International journal of pharmaceutics 2007, 343 (1-2), 34-40.

(46) Hosny, K. M. Ciprofloxacin as ocular liposomal hydrogel. Aaps PharmScitech 2010, 11 (1), 241-246.

(47) Santos, A.; Altamirano-Vallejo, J. C.; Navarro-Partida, J.; González-De la Rosa, A.; Hsiao, J. H. Breaking down the barrier: topical liposomes as nanocarriers for drug delivery into the posterior segment of the eyeball. Role of Novel Drug Delivery Vehicles in Nanobiomedicine 2019, 23.

(48) Prausnitz, M. R.; Noonan, J. S. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J. Pharm. Sci. 1998, 87 (12), 1479-1488.

(49) Ramsay, E.; Del Amo, E. M.; Toropainen, E.; Tengvall-Unadike, U.; Ranta, V.-P.; Urtti, A.; Ruponen, M. Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye. European Journal of Pharmaceutical Sciences 2018, 119, 83-89.

(50) Hámalainen, K.-M.; Kananen, K.; Auriola, S.; Kontturi, K.; Urtti, A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Investigative ophthalmology & visual science 1997, 38 (3), 627-634.

(51) Dartt, D. A. Encyclopedia of the Eye; Academic Press, 2010.

(52) Hodges, R. R.; Dartt, D. A. Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins. Experimental eye research 2013, 117, 62-78.